Live attenuated influenza vaccine (LAIV) represent reassortant viruses with hemagglutinin (HA) and neuraminidase (NA) gene segments inherited from circulating wild-type (WT) parental influenza viruses recommended for inclusion into seasonal vaccine formulation, and the 6 internal protein-encoding gene segments from cold-adapted attenuated master donor viruses (genome composition 6:2). In this study, we describe the obstacles in developing LAIV strains while taking into account the phenotypic peculiarities of WT viruses used for reassortment. Genomic composition analysis of 849 seasonal LAIV reassortants revealed that over 80% of reassortants based on inhibitor-resistant WT viruses inherited WT NA, compared to 26% of LAIV reassortants based ...
The threat of future influenza pandemics and their potential for rapid spread, morbidity, andmortali...
BACKGROUND: Influenza A virus displays strong reassortment characteristics, which enable it to achie...
Neuraminidase inhibitors (NAI) remain the mainstay therapeutic option against influenza infections. ...
Abstract: Live attenuated influenza vaccine (LAIV) represent reassortant viruses with hemagglutinin ...
Mutations of the conserved residues of influenza virus neuraminidase (NA) that are associated with N...
BACKGROUND: Influenza A virus vaccines undergo yearly reformulations due to the antigenic variabilit...
BACKGROUND: Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassort...
Amino acid substitutions in influenza virus neuraminidase (NA) that cause resistance to neuraminidas...
The cold-adapted, temperature sensitive and attenuated influenza master donor viruses A/Lenin- grad/...
Effective antiviral drugs are essential for early control of an influenza pandemic. It is therefore ...
Epidemics and pandemics of influenza continue to be major global health threats. Control measures ag...
Background: Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassort...
AbstractWidespread use of a live-attenuated influenza vaccine (LAIV) in the United States (licensed ...
Influenza A virus displays strong reassortment characteristics, which enable it to achieve adaptatio...
Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-M...
The threat of future influenza pandemics and their potential for rapid spread, morbidity, andmortali...
BACKGROUND: Influenza A virus displays strong reassortment characteristics, which enable it to achie...
Neuraminidase inhibitors (NAI) remain the mainstay therapeutic option against influenza infections. ...
Abstract: Live attenuated influenza vaccine (LAIV) represent reassortant viruses with hemagglutinin ...
Mutations of the conserved residues of influenza virus neuraminidase (NA) that are associated with N...
BACKGROUND: Influenza A virus vaccines undergo yearly reformulations due to the antigenic variabilit...
BACKGROUND: Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassort...
Amino acid substitutions in influenza virus neuraminidase (NA) that cause resistance to neuraminidas...
The cold-adapted, temperature sensitive and attenuated influenza master donor viruses A/Lenin- grad/...
Effective antiviral drugs are essential for early control of an influenza pandemic. It is therefore ...
Epidemics and pandemics of influenza continue to be major global health threats. Control measures ag...
Background: Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassort...
AbstractWidespread use of a live-attenuated influenza vaccine (LAIV) in the United States (licensed ...
Influenza A virus displays strong reassortment characteristics, which enable it to achieve adaptatio...
Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-M...
The threat of future influenza pandemics and their potential for rapid spread, morbidity, andmortali...
BACKGROUND: Influenza A virus displays strong reassortment characteristics, which enable it to achie...
Neuraminidase inhibitors (NAI) remain the mainstay therapeutic option against influenza infections. ...